rhinosinusitis%20-%20acute,%20bacterial
RHINOSINUSITIS - ACUTE, BACTERIAL
Acute bacterial rhinosinusitis is the mucosal inflammation of the nose and paransal sinuses caused by bacteria lasting >10 days for up to 4 weeks or symptoms worsening for 5-7 days within 10 days.
It is often preceded by a viral upper respiratory tract infection.
Signs and symptoms are nonspecific and typically difficult to differentiate from viral upper respiratory tract infection.
There is fever with nasal obstruction/congestion or anterior and/or posterior purulent drainage, with or without facial pressure/pain/fullness and reduction/loss of smell.
Streptococcus pneumoniae and unencapsulated strains of Haemophilus influenzae cause half of acute rhinosinusitis cases.

Definition

  • Mucosal inflammation of the nose & paranasal sinuses caused by bacteria lasting >10 days for up to 4 weeks or symptoms worsening after 5-7 days
  • Often preceded by a viral upper respiratory tract infection (URTI) upper respiratory tract infection (URTI), rhinitis or other conditions that impair local or systemic immune function (eg nonallergic rhinitis, dental infection, mechanical obstruction of the nose, cystic fibrosis, ciliary dysfunction, immunodeficiency that impair the sinus drainage)
  • Incidence in women is higher than men

Etiology

  • S pneumoniae & unencapsulated strains of H influenzae cause approximately 75% of acute rhinosinusitis cases
  • M catarrhalis account for 2-10% of the cases & is more common among children
  • 3-7% of the cases may be due to S pyogenes & anaerobic bacteria
  • S aureus & other Streptococcal sp may occasionally cause rhinosinusitis
  • Rarely Gram-negative bacilli are recovered in cases of acute rhinosinusitis
  • Microaerophilic & anaerobic bacteria may be identified & isolated if the acute bacterial rhinosinusitis (ARBS) is due to the extension of dental root infection to the sinus cavity

Pathophysiology

  • Occurs as a complication of a viral infection
    • Can be associated with rhinitis or other conditions that obstruct the nose or impair immune function (local or systemic)

Signs and Symptoms

  • Signs and symptoms are nonspecific and it is typically difficult to differentiate from viral upper respiratory tract infection (URTI)
  • There is fever with nasal obstruction/congestion or anterior and/or posterior purulent drainage, with or without
    • Facial pressure/pain/fullness
    • Reduction/loss of smell
  • Other signs & symptoms include fatigue, headache, ear pressure/discomfort, throat pain, halitosis, maxillary dental pain, facial swelling or periorbital edema, cough

Risk Factors

  • Most common predisposing factors to acute bacterial rhinosinusitis (ABRS) is viral upper respiratory tract infection (URTI)
  • Other factors:
    • Presence of medical conditions (eg allergic rhinitis, cystic fibrosis, immunodeficiency, etc)
    • Irritants (eg environmental tobacco smoke, air pollution, chlorine)
    • Anatomic (eg deviated septum, adenoidal hypertrophy, immotile cilia, polyps, tumors & foreign bodies)
    • Odontogenic sources
    • Medications (eg overuse of topical decongestants, cocaine abuse)
    • Trauma (eg dental procedure, diving)
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Jairia Dela Cruz, 22 Aug 2018
Fast food consumption appears to be detrimental to health, with hamburgers having been shown to have a dose-response association with the risk of asthma.
Roshini Claire Anthony, 05 Sep 2018

Patients admitted to the intensive care unit (ICU) with severe influenza have an elevated risk of developing invasive pulmonary aspergillosis, particularly if they are immunocompromised at time of admission, a recent study has shown.

Radha Chitale, 06 Apr 2016
An investigational device monitoring fluid accumulation in the lungs significantly reduced hospitalization due to heart failure and death by any cause among heart failure patients compared with standard monitoring and treatment methods, according to results from the IMPEDANCE-HF trial reported during the recent ACC meeting in Chicago, Illinois, US.